In summary, in randomized clinical trials using validated questionnaires adjunctive progestin with estrogens did not increase depressive symptoms of postmenopausal women. Overall, depressive symptoms decreased with estrogen-progestin HT but also with estrogen alone. The decrease was not so pronounced to differ from controls on placebo. HT does not hamper the clinical efficacy of fluoxetine. The scarcity of randomized studies makes it difficult to determine the exact effect on depressive symptoms of different types of progestins. Project protocol registered in PROSPERO, registration number CRD42023454099.
Keyphrases
- depressive symptoms
- postmenopausal women
- double blind
- placebo controlled
- phase iii
- social support
- bone mineral density
- open label
- sleep quality
- clinical trial
- estrogen receptor
- phase ii
- randomized controlled trial
- psychometric properties
- polycystic ovary syndrome
- type diabetes
- study protocol
- metabolic syndrome
- pregnancy outcomes
- pregnant women
- adipose tissue
- body composition
- skeletal muscle
- case control
- molecular dynamics